
Nura Issa
Nura Izath is a Ugandan computer engineer and digital health innovator, founder and CEO of Neosave Technologies, developer of the Autothermo newborn vital-signs wearable.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
Sep 1, 2026
AI Medical Devices: Are We Using Them Before We Know They Work?
10:01
10:11
12:50
9:52
Is there enough evidence to show that these medical devices, even if they are just collecting data, that they're going to do it properly in these different groups?

Nura IssaGUEST
Yes, to be confident that they can work across all those different groups, they must be tested during the clinical trial phases.

Nura IssaGUEST
So you have to test among the different groups so that you have evidence that it actually works in all those groups.
12:37
And what about countries like Uganda demanding we need more testing in our populations before these can be approved and rolled out? Are you in a position to be able to do that?

Nura IssaGUEST
Yes, that gets back to the regulatory, the ministries of health, the innovators, because I mean, the innovators, when we are innovating, we are aimed at having these products out in the market without the test, but then the different agencies like the Ministry of Health, if they could have these systems strengthened and defined that every innovator should go through this process, or every product that is coming was developed out of Uganda should follow this particular framework and have all those devices tested among these patients, then that would be an easier way to follow.
